Patient savings card(s)

For eligible commercial patients pay as little as $30 for GLUCAGON.

Each card has a unique ID number. Please do not make copies.

*Offer good until 12/31/2022 for up to 12 months. Patients must have commercial drug insurance coverage with insurance provider coverage for Lilly GLUCAGON to pay as little as $30 for a maximum of 3 Lilly GLUCAGON emergency kits per prescription fill. Offer subject to a monthly cap of $100 and a separate annual cap $1200. Offer void where prohibited by law. Patient is responsible for any applicable taxes, fees, or amounts exceeding monthly or annual caps. This offer is invalid for patients without commercial drug insurance or whose prescription claims for GLUCAGON are eligible to be reimbursed, in whole or in part, by any governmental program, including, without limitation, Medicaid, Medicare, Medicare Part D, Medigap, DoD, VA, TRICARE®/CHAMPUS, or any state patient or pharmaceutical assistance program. Offer void where prohibited by law and subject to change or discontinue without notice. Card activation is required. Subject to additional terms and conditions, which can be found at here .


GLUCAGON is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes mellitus, and as a diagnostic aid for use during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract in adult patients.

Important Safety Information for GLUCAGON


GLUCAGON is contraindicated in patients with pheochromocytoma because of the risk of substantial increase in blood pressure, insulinoma because of the risk of hypoglycemia, and known hypersensitivity to glucagon or any of the excipients in GLUCAGON. Allergic reactions have been reported with glucagon and include anaphylactic shock with breathing difficulties and hypotension. Additionally, GLUCAGON is contraindicated in patients with glucagonoma when used as a diagnostic aid because of the risk of hypoglycemia.

Warnings and Precautions

GLUCAGON is contraindicated in patients with pheochromocytoma because glucagon may stimulate the release of catecholamines from the tumor. If the patient develops a substantial increase in blood pressure and a previously undiagnosed pheochromocytoma is suspected, 5 to 10 mg of phentolamine mesylate, administered intravenously, has been shown to be effective in lowering blood pressure.

In patients with insulinoma, administration of glucagon may produce an initial increase in blood glucose; however, GLUCAGON administration may directly or indirectly (through an initial rise in blood glucose) stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. GLUCAGON is contraindicated in patients with insulinoma. If a patient develops symptoms of hypoglycemia after a dose of GLUCAGON, give glucose orally or intravenously.

Allergic reactions have been reported with glucagon; these include generalized rash, and in some cases anaphylactic shock with breathing difficulties and hypotension. GLUCAGON is contraindicated in patients with a prior hypersensitivity reaction.

GLUCAGON is effective in treating hypoglycemia only if sufficient hepatic glycogen is present. Patients in states of starvation with adrenal insufficiency or chronic hypoglycemia may not have adequate levels of hepatic glycogen for GLUCAGON administration to be effective. Patients with these conditions should be treated with glucose.

Necrolytic Migratory Erythema (NME), a skin rash commonly associated with glucagonomas (glucagon-producing tumors) and characterized by scaly, pruritic erythematous plaques, bullae, and erosions, has been reported post marketing following continuous glucagon infusion. NME lesions may affect the face, groin, perineum, and legs or be more widespread. In the reported cases, NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. Should NME occur, consider whether the benefits of continuous glucagon infusion outweigh the risks.

Treatment with GLUCAGON in patients with diabetes mellitus may cause hyperglycemia. Monitor diabetic patients for changes in blood glucose levels during treatment and treat if indicated.

GLUCAGON may increase myocardial oxygen demand, blood pressure, and pulse rate which may be life-threatening in patients with cardiac disease. Cardiac monitoring is recommended in patients with cardiac disease during use of GLUCAGON as a diagnostic aid, and an increase in blood pressure and pulse rate may require therapy.

Glucagon administered to patients with glucagonoma may cause secondary hypoglycemia. Test patients suspected of having glucagonoma for blood levels of glucagon prior to use as a diagnostic aid as GLUCAGON is contraindicated in this setting.

Adverse Reactions

GLUCAGON adverse reactions include: injection site reactions, nausea, vomiting, headache, dizziness, asthenia, pallor, diarrhea, somnolence, and decreased blood pressure.

Drug Interactions

Patients taking beta-blockers may have a transient increase in pulse and blood pressure.

In patients taking indomethacin GLUCAGON may lose its ability to raise glucose or may produce hypoglycemia.

Concomitant use of anticholinergic drugs with GLUCAGON for use as a diagnostic aid is not recommended.

GLUCAGON may increase the anticoagulant effect of warfarin.

Monitor blood glucose when GLUCAGON is used as a diagnostic aid in patients receiving insulin.

See Full Prescribing Information and Patient Information provided. Please see Instructions for Use included with the device.